EAM
CRNX

Eventide Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Eventide Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-609,014
Closed -$31.1M – 227
2024
Q4 		$31.1M Sell
609,014
-126,074
-17% -$7.05M 0.57% 62
2024
Q3 		$37.6M Hold
735,088
– – 0.65% 52
2024
Q2 		$32.9M Sell
735,088
-324,545
-31% -$15M 0.56% 58
2024
Q1 		$49.6M Hold
1,059,633
– – 0.78% 46
2023
Q4 		$37.7M Buy
1,059,633
+40,851
+4% +$1.25M 0.62% 56
2023
Q3 		$30.3M Buy
1,018,782
+584,014
+134% +$12M 0.54% 55
2023
Q2 		$7.83M Hold
434,768
– – 0.13% 124
2023
Q1 		$6.98M Buy
+434,768
New +$8.05M 0.13% 124
2021
Q2 		– Sell
-241,140
Closed -$3.69M – 154
2021
Q1 		$3.69M Sell
241,140
-158,860
-40% -$2.46M 0.05% 139
2020
Q4 		$5.64M Sell
400,000
-947,000
-70% -$13.2M 0.09% 123
2020
Q3 		$21.1M Hold
1,347,000
– – 0.41% 71
2020
Q2 		$23.6M Buy
1,347,000
+400,000
+42% +$6.82M 0.51% 63
2020
Q1 		$13.9M Hold
947,000
– – 0.45% 67
2019
Q4 		$23.8M Hold
947,000
– – 0.67% 59
2019
Q3 		$14.2M Buy
947,000
+143,161
+18% +$2.78M 0.47% 67
2019
Q2 		$20.1M Buy
803,839
+419,839
+109% +$10.4M 0.61% 60
2019
Q1 		$8.74M Buy
384,000
+260,775
+212% +$6.41M 0.3% 75
2018
Q4 		$3.7M Hold
123,225
– – 0.16% 92
2018
Q3 		$3.53M Buy
+123,225
New +$3.66M 0.13% 106

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eventide Asset Management's CRNX Position: Q1 2025 in Review

Eventide Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 609,014 shares — an estimated $31.1M sold.

Eventide Asset Management first reported a position in CRNX in Q3 2018 and held it in 19 quarters. The position peaked at $49.6M in Q1 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Eventide Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Eventide Asset Management sold 609,014 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $31.1M.
  • Eventide Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 19 quarters.
  • Eventide Asset Management's Crinetics Pharmaceuticals position peaked at $49.6M in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Eventide Asset Management's 13F filing for Q1 2025, filed 15 May 2025.